MedTrace Logo

Serial Echocardiography After Subarachnoid Hemorrhage

NCT00123695 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 350

Last updated 2008-03-27

No results posted yet for this study

Summary

There is increasing interest in myocardial abnormalities following central nervous system events, such as subarachnoid hemorrhage (SAH). These cardiac abnormalities include ECG changes, decreased cardiac output, decreased blood pressure, specific cardiac enzyme elevations, and segmental wall motion abnormalities (SWMA). Interestingly, wall motion abnormalities and ECG changes have shown to be reversible, and therefore the dysfunction has been described as neurogenic myocardial stunning.

The pathophysiology of cardiac dysfunction following SAH has not yet been fully elucidated. Many reports (mainly case reports) have been published, but so far no study has investigated the frequency of these abnormalities in a prospective manner, have correlated the occurrence of the different cardiac abnormalities, and have assessed which clinical variables can predict cardiac dysfunction. And only a limited number of studies have related neurological outcome with cardiac dysfunction.

Conditions

  • Subarachnoid Hemorrhage
  • Myocardial Stunning
  • Takotsubo Cardiomyopathy

Sponsors & Collaborators

  • Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

    collaborator OTHER

  • UMC Utrecht

    collaborator OTHER

  • University Medical Center Groningen

    collaborator OTHER

  • Erasmus Medical Center

    collaborator OTHER

  • Amsterdam UMC, location VUmc

    lead OTHER

Principal Investigators

  • Frans C Visser, MD PhD · Amsterdam UMC, location VUmc

  • Ivo A van der Bilt, MD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

  • Gabriel J Rinkel, MD PhD · UMC Utrecht

  • Arthur A Wilde, MD PhD · Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Eligibility

Min Age
10 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00123695 on ClinicalTrials.gov